Related Experiment Video
Updated: May 30, 2026
06:08
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high
Markus Joerger1, Andrés J M Ferreri, Stephan Krähenbühl
1Department of Oncology and Hematology, Cantonal Hospital, Rorschacherstrasse 95, 9007 St Gallen, Switzerland. markus.joerger@kssg.ch
British Journal of Clinical Pharmacology
|August 16, 2011
Summary
A new dosing algorithm for high-dose methotrexate (HDMTX) uses 24-hour plasma concentrations to improve treatment targeting for primary CNS lymphoma patients. This method significantly increases the proportion of patients within the desired AUC(MTX) range.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Oncology
- Clinical Pharmacology
Background:
- Optimal dosing for high-dose methotrexate (HDMTX) in primary CNS lymphoma (PCNSL) lacks consensus.
- Achieving a target area under the concentration-time curve (AUC) for methotrexate (MTX) is crucial for efficacy and safety.
Purpose of the Study:
- To develop a practical dosing algorithm for HDMTX.
- To target a specific AUC(MTX) range of 1000-1100 µmol·l⁻¹·h in PCNSL patients.
- To simplify dose adjustments based on early plasma concentrations.
Main Methods:
- A population pharmacokinetic model was utilized with a pooled dataset of 131 patients.
- Simulations of 10,000 patients were performed to test a dosing algorithm based on 24-hour MTX plasma concentrations (C24).
- Simulated patients received four cycles of HDMTX, with dose adjustments for cycles 2-4 based on C24.
Main Results:
- The algorithm suggests dose adjustments from +75% to -35% based on C24 levels.
- The proportion of patients within the target AUC(MTX) range increased from 11% (standard dosing) to 35% (adjusted dosing).
- A significant reduction in interindividual variability of MTX exposure was observed.
Conclusions:
- A simple, practical dosing algorithm for HDMTX using C24 has been developed.
- Data simulations indicate potential for improved target AUC attainment and reduced MTX exposure variability.
- Further clinical assessment in PCNSL patients is warranted to confirm the benefit of this dosing algorithm.
Related Concept Videos
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.